Ulcerative colitis
Conditions
Interventions
None listed
Sponsors
Kyorin University School of Medicine
Sapporo Medical University, Dept. Gastroenterology and Hepatology Toho University Sakura Medical Center, Dept. Gastroenterology and Hepatology Kitasato University Kitasato Institute Hospital, Dept. Gastroenterology and Hepatology
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1)Subjects diagnosed with ulcerative colitis. (2)Subjects who are naive to molecular-targeted medications and plan to start adhesion molecule inhibitors. (3)Subjects who are 16 years old or older when providing written consent. (4)Subjects who understand, decide to take part in this study and provide written consent by themselves. Minors need consent from themselves as well as their guardians.
Exclusion criteria
Exclusion criteria: (1)Subjects who don't provide written consent by themselves or their guardians. (2)Subjects who had total or partial colectomy. (3)Subjects diagnosed with proctitis or an undetermined disease type. (4)Subjects suspected concomitant colitis due to other reasons. (5)Subjects with an emergent, critical condition of ulcerative colitis (e.g., fulminant UC, toxic megacolon, uncontrollable bleeding).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| exploring the factors related to the endoscopic improvement at 6 months after starting the remission induction therapy. | — |
Countries
Japan
Contacts
Public ContactJun Miyoshi
Kyorin University School of Medicine Department of Gastroenterology and Hepatology
Outcome results
None listed